China Pharma Holdings (CPHI) Non-Current Debt (2013 - 2025)
China Pharma Holdings' (CPHI) quarterly Non-Current Debt came in at $1.3 million in Q2 2025, down 5.93% YoY from $1.4 million in Q2 2024, and down 5.25% on a QoQ basis from $1.4 million in Q1 2025.
China Pharma Holdings (CPHI) Non-Current Debt (2013 - 2025) Analysis & Trends
China Pharma Holdings (CPHI) has 13 years of Non-Current Debt data on file, last reported at $1.3 million in Q2 2025.
- Quarterly Non-Current Debt fell 5.93% year-over-year to $1.3 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.3 million (down 5.93% YoY) and the FY2024 annual result came in at $1.4 million, down 1.47% from the prior year.
- Non-Current Debt slipped to $1.3 million in Q2 2025, from $1.4 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.5 million in Q3 2022 to a low of $325072.0 in Q2 2021.
- A 5-year average of $1.2 million and a median of $1.4 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2021 — Non-Current Debt slumped 83.56% — and 2022, when it jumped 92.5%.
- Tracing CPHI's Non-Current Debt over 5 years: stood at $1.2 million in 2021, then surged by 30.6% to $1.5 million in 2022, then fell by 8.32% to $1.4 million in 2023, then decreased by 1.47% to $1.4 million in 2024, then declined by 5.12% to $1.3 million in 2025.
- The last three Non-Current Debt figures came in at $1.3 million (Q2 2025), $1.4 million (Q1 2025), and $1.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 130.00 Mn |
| 10 | China Pharma Holdings | 42.35 Mn | 42.04 Mn | 83,566.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.43 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 1.39 Mn |
| Sep 30, 2022 | 1.54 Mn |
| Dec 31, 2021 | 1.18 Mn |
| Sep 30, 2021 | 800,000.00 |
| Jun 30, 2021 | 325,072.00 |
| Mar 31, 2021 | 852,191.00 |
| Dec 31, 2020 | 904,228.00 |
| Sep 30, 2020 | 500,000.00 |
| Jun 30, 2020 | 1.98 Mn |
| Mar 31, 2020 | 2.12 Mn |
| Dec 31, 2019 | 2.15 Mn |
| Sep 30, 2019 | 2.12 Mn |
| Jun 30, 2019 | 4.22 Mn |